Increased mortality with elevated plasma endothelin-1 in acute heart failure: An ASCEND-HF biomarker substudy

European Journal of Heart Failure

Volumn 18, Issue 3, 2016, Pages 290-297

  Perez, Antonio L ^a   Grodin, Justin L ^a   Wu, Yuping ^b   Hernandez, Adrian F ^c   Butler, Javed ^d   Metra, Marco ^e   Felker, G Michael ^c   Voors, Adriaan A ^f   McMurray, John J ^g   Armstrong, Paul W ^h   Starling, Randall C ^a   O'Connor, Christopher M ^c   Tang, W H Wilson ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND STATE UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e UNIVERSITY OF BRESCIA   (Italy)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Acute heart failure; Endothelin 1; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIN 1; NESIRITIDE; NITROGEN; PLACEBO; TROPONIN I; UREA; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; ACUTE DISEASE; BLOOD; HEART FAILURE; HOSPITAL MORTALITY; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACUTE DISEASE; AGED; BIOMARKERS; ENDOTHELIN-1; FEMALE; HEART FAILURE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84949954669     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.456     Document Type: Article

References (30)

1. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R,. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85: 504-509.
2. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ,. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739.
3. Taddei S, Virdis A, Ghiadoni L, Sudano I, Notari M, Salvetti A,. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation 1999; 100: 1680-1683.
4. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ,. Plasma endothelin in chronic heart failure. Circulation 1992; 85: 1374-1379.
5. Lerman A, Kubo SH, Tschumperlin LK, Burnett JC Jr., Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J Am Coll Cardiol 1992; 20: 849-853.
6. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K,. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-1579.
7. Pousset F, Isnard R, Lechat P, Kalotka H, Carayon A, Maistre G, Escolano S, Thomas D, Komajda M,. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 1997; 18: 254-258.
8. Hulsmann M, Stanek B, Frey B, Sturm B, Putz D, Kos T, Berger R, Woloszczuk W, Maurer G, Pacher R,. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 1998; 32: 1695-1700.
9. Dschietzig T, Bartsch C, Richter C, Laule M, Baumann G, Stangl K,. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB. Circulation Res 2003; 92: 32-40.
10. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF, Jr., Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalan R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Mendez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM., Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365: 32-43.
11. Hernandez AF, O'Connor CM, Starling RC, Reist CJ, Armstrong PW, Dickstein K, Lorenz TJ, Gibler WB, Hasselblad V, Komajda M, Massie B, McMurray JJ, Nieminen M, Rouleau JL, Swedberg K, Califf RM,. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J 2009; 157: 271-277.
12. Felker GM, Hasselblad V, Tang WH, Hernandez AF, Armstrong PW, Fonarow GC, Voors AA, Metra M, McMurray JJ, Butler J, Heizer GM, Dickstein K, Massie BM, Atar D, Troughton RW, Anker SD, Califf RM, Starling RC, O'Connor CM,. Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. Eur J Heart Fail 2012; 14: 1257-1264.
13. Kalogeropoulos AP, Tang WH, Hsu A, Felker GM, Hernandez AF, Troughton RW, Voors AA, Anker SD, Metra M, McMurray JJ, Massie BM, Ezekowitz JA, Califf RM, O'Connor CM, Starling RC, Butler J,. High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. J Cardiac Fail 2014; 20: 319-326.
14. Tang WH, Dupont M, Hernandez AF, Voors AA, Hsu AP, Felker GM, Butler J, Metra M, Anker SD, Troughton RW, Gottlieb SS, McMurray JJ, Armstrong PW, Massie BM, Califf RM, O'Connor CM, Starling RC,. Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. JACC Heart Fail 2015; 3: 40-49.
15. Todd J, Freese B, Lu A, Held D, Morey J, Livingston R, Goix P,. Ultrasensitive flow-based immunoassays using single-molecule counting. Clin Chem 2007; 53: 1990-1995.
16. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T,. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
17. Kawanabe Y, Nauli SM,. Endothelin. Cell Mol Life Sci 2011; 68: 195-203.
18. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S,. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348: 730-732.
19. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T,. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990; 348: 732-735.
20. Luscher TF, Barton M,. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102: 2434-2440.
21. Dupuis J, Stewart DJ, Cernacek P, Gosselin G,. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996; 94: 1578-1584.
22. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ,. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-1123.
23. Nootens M, Kaufmann E, Rector T, Toher C, Judd D, Francis GS, Rich S,. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 1995; 26: 1581-1585.
24. Torre-Amione G, Young JB, Durand J, Bozkurt B, Mann DL, Kobrin I, Pratt CM,. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation 2001; 103: 973-980.
25. Torre-Amione G, Young JB, Colucci WS, Lewis BS, Pratt C, Cotter G, Stangl K, Elkayam U, Teerlink JR, Frey A, Rainisio M, Kobrin I,. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2003; 42: 140-147.
26. O'Connor CM, Gattis WA, Adams KF Jr, Hasselblad V, Chandler B, Frey A, Kobrin I, Rainisio M, Shah MR, Teerlink J, Gheorghiade M,. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol 2003; 41: 1452-1457.
27. Kaluski E, Kobrin I, Zimlichman R, Marmor A, Krakov O, Milo O, Frey A, Kaplan S, Krakover R, Caspi A, Vered Z, Cotter G,. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol 2003; 41: 204-210.
28. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I,. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007; 298: 2009-2019.
29. Bianciotti LG, de Bold AJ,. Modulation of cardiac natriuretic peptide gene expression following endothelin type A receptor blockade in renovascular hypertension. Cardiovasc Res 2001; 49: 808-816.
30. Kohno M, Yokokawa K, Horio T, Yasunari K, Murakawa K, Takeda T,. Atrial and brain natriuretic peptides inhibit the endothelin-1 secretory response to angiotensin II in porcine aorta. Circ Resh 1992; 70: 241-247.